Hypoxenum is an adaptogen developed in 1976 by a group of scientists in the Institute of Macromolecular Compounds of the Academy of Sciences of the USSR, Leningrad. The active compound of Hypoxen is Sodium salt of (poly-(2,5-dihydroxy-phenylene))-4-thiosulfonic acid. Hypoxenum and coenzyme Q10 have a similar structure.
Hypoxen was shown to have antihypoxic and antioxidant effect and can be used by healthy people with reduced performance in extreme situations and adverse weather conditions, e.g. Far North, highlands, etc. Hypoxenum is used by athletes to improve physical performance, yet it is not on the WADA Prohibited list. Apart from that, the drug was also shown to be effective in patients suffering from alcohol abuse problems as it can decrease cravings, improve mood, lower anxiety and asthenia.
Hypoxen is also used to treat illnesses. In particular, it can be used in the combination therapy of conditions associated with hypoxia: severe injuries, burns, major surgery, blood loss, as well as asthma and obstructive bronchitis, pneumonia and insufficient oxygen supply to the issues. Moreover, Hypoxenum reduces the amount of damage caused to the heart by myocardial infarction; the drug also activates the functional activity of monocytes in patients with viral hepatitis, recurrent herpes, influenza and acute respiratory viral infections (ARVI).
In 1996, the drug was approved for medical use and has been sold without prescription in Russia since then.
Off-label use of Hypoxenum includes treatment of patients with addictive disorders such as the relief of alcohol withdrawal. As was shown in this study Hypoxenum possesses high efficacy as a drug used to relief withdrawal symptoms in the period of postabstinence.
The active compound of the drug is also patented in the USA: https://patents.google.com/patent/US6117970A/en.
The drug is produced on a pharmaceutical factory ZAO “Korporatsiya OLIFEN”, Moscow, Russia.
Hypoxenum prevents lipid peroxidation and stimulates its products destruction. It stimulates the oxidation of accumulated reduced equivalents during the post-hypoxic period due to Nicotinamide adenine dinucleotide phosphate or NADP⁺. It optimises mitochondrial function, enhances tissue respiration and mitochondria aerobic respiration, reduces the hypoxia negative effects as a result increasing endurance and mental performance.
Antihypoxic and antioxidant effects. Hypoxenum has electron acceptor properties due to its polyphenolic structure, shunts the electron transport chain of mitochondria and enhances tissue respiration. The thiosulfate group gives Hypoxenum a pronounced antiradical and antioxidant effect.